| Year | Citation (first author journal) | URL | Evidence type (primary/review/database) | Key findings relevant to UBAC2 (function/pathway/localization/domains) | Key quantitative/statistical data (p-values, ORs, n) | Notes/limitations |
|---|---|---|---|---|---|---|
| 2024 | He, *EMBO Journal* | https://doi.org/10.1038/s44318-024-00232-z | Primary | Identifies human UBAC2 as an ER-resident ER-phagy receptor. UBAC2 contains a cytoplasmic canonical LIR that binds GABARAP; MARK2 phosphorylates UBAC2 at S223, promoting dimerization and stronger GABARAP binding. UBAC2-mediated ER-phagy restrains UPR/inflammatory signaling and protects against DSS colitis. UBAC2 also undergoes autophagic turnover during ER stress/starvation. (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000012, pqac-00000014) | HeLa ER-phagy reporter quantified across 3 biological replicates; 20 cells scored/condition in microscopy analyses; DSS colitis experiments used n=6 mice/group; multiple comparisons reported including p<0.0001, p=0.0100, p=0.0071, p=0.0012, p=0.0080. (pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000014) | Strongest recent mechanistic study; extends UBAC2 function beyond ERAD into selective autophagy. Context excerpts do not provide all effect sizes/fold changes. |
| 2019 | Choi, *Science* | https://doi.org/10.1126/science.aau0812 | Primary | Places UBAC2 in an ER-localized LMBR1L-GP78-UBAC2 complex that promotes ubiquitin-mediated degradation of FZD6/LRP6 and helps limit Wnt/β-catenin signaling in lymphocytes. Supports ER quality-control/ERAD-like function and ER localization. (pqac-00000005) | Paper reports impaired lymphoid development/function in mutant mice and restoration experiments involving β-catenin knockout, but quantitative values were not present in the available excerpt. (pqac-00000005) | Direct primary evidence for pathway-specific UBAC2 function, but excerpt does not state membrane topology or UBA-domain position. |
| 2023 | Bhaduri, *Cold Spring Harbor Perspectives in Biology* | https://doi.org/10.1101/cshperspect.a041248 | Review | Reviews rhomboid superfamily roles in ER protein quality control and includes UBAC2 among rhomboid-like proteins linked to ERAD/proteostasis. Helps place UBAC2 in current ER quality-control framework. (pqac-00000000) | No UBAC2-specific quantitative statistics in available excerpt. | High-authority recent review; useful for current conceptual understanding, but mostly secondary synthesis rather than direct UBAC2 experiments. |
| 2020 | Adrain, *FEBS Journal* | https://doi.org/10.1111/febs.15548 | Review | Describes UBAC2 as an ER-localized rhomboid pseudoprotease with a conserved C-terminal UBA domain; links UBAC2 to UBXD8, GP78-ERAD, delivery of substrates to GP78, and LMBR1L-GP78-UBAC2-mediated Wnt regulation. Notes Derlin-like behavior and unresolved physiology. (pqac-00000001, pqac-00000007) | No new quantitative UBAC2 statistics in excerpt. | Strong synthesis of mechanistic literature; some claims are review-level interpretations and precise physiological roles remain incompletely established. |
| 2020 | Kandel, *BBA Mol Cell Res* | https://doi.org/10.1016/j.bbamcr.2020.118793 | Review | Summarizes UBAC2 as a rhomboid-like multi-pass membrane protein with a C-terminal UBA domain that binds polyubiquitin; UBAC2 knockdown stabilizes mutant α1-antitrypsin (an ERAD substrate) and UBAC2 restricts UBXD8 trafficking from ER to lipid droplets, linking proteostasis to lipid homeostasis. (pqac-00000002) | Quantitative values not included in excerpt; cites primary data that recombinant UBA binds polyubiquitin and knockdown stabilizes mutant α1-antitrypsin. (pqac-00000002) | Valuable for integrating ERAD and lipid-droplet biology; secondary source. |
| 2016 | Lemberg, *Seminars in Cell & Developmental Biology* | https://doi.org/10.1016/j.semcdb.2016.06.022 | Review | Classifies UBAC2 as a rhomboid-family pseudoprotease predicted to bind ubiquitin via a conserved cytoplasmic C-terminal UBA domain; places it in the ERAD network with gp78 and identifies UBAC2 as an ER tether for UBXD8, affecting lipid-droplet trafficking and triglyceride turnover. (pqac-00000003) | No quantitative UBAC2-specific statistics in excerpt. | Foundational review; older and predates ER-phagy findings. |
| 2013 | Olzmann, *Cold Spring Harbor Perspectives in Biology* | https://doi.org/10.1101/cshperspect.a013185 | Review | Early authoritative ERAD review explicitly mentions UBAC2 as a recently identified UBA-domain-containing, rhomboid-like factor in mammalian ERAD, helping establish the historical basis for UBAC2’s ER quality-control annotation. (pqac-00000000) | No UBAC2-specific quantitative data in available excerpt. | Important historical context, but limited UBAC2 detail in excerpt. |
| 2012 | Hou, *Arthritis Research & Therapy* | https://doi.org/10.1186/ar3789 | Primary genetics/functional | Validates UBAC2 as a Behçet’s disease susceptibility locus in Han Chinese. Promoter SNP rs3825427 risk T allele reduces promoter activity and lowers UBAC2 transcript variant 1 in PBMCs/skin; variant 1 is decreased in BD, while variant 2 is increased in BD skin. (pqac-00000015, pqac-00000016, pqac-00000017, pqac-00000018, pqac-00000019) | Two-stage study totaling 477 BD patients and 1,334 controls; rs9513584 Pc=0.018, OR=1.4; rs3825427 combined Pc=6.9×10^-6, OR=1.5; rs9517668 combined Pc=3.3×10^-4, OR=1.4; rs9517701 combined Pc=2.9×10^-5, OR=1.4; rs3825427 promoter assay P=0.002; transcript variant 1 genotype-expression P=0.045 and P=0.025; BD vs control expression P=0.025 and P=0.047; variant 2 in BD skin P=0.004. (pqac-00000015, pqac-00000016, pqac-00000017, pqac-00000018) | Strong disease-association and functional-regulatory evidence, but does not define biochemical mechanism of UBAC2 protein action. |
| 2011 | Nan, *Human Molecular Genetics* | https://doi.org/10.1093/hmg/ddr287 | Primary genetics | GWAS implicates the UBAC2/PHGDHL1 region in skin cancer susceptibility, supporting medical relevance of the locus. (pqac-00000020) | Discovery 2,045 BCC cases/6,013 controls; replication 1,426 cases/4,845 controls. rs7335046 near UBAC2: BCC OR 1.26 (95% CI 1.18–1.34), P=2.9×10^-8; SCC OR 1.21 (95% CI 1.02–1.44), P=0.03; rs12210050[T] SCC OR 1.35 (95% CI 1.16–1.57), P=7.6×10^-5. (pqac-00000020) | Locus-level association only; does not establish UBAC2 as the causal effector gene or define function. |
| Current | Open Targets Platform | https://platform.opentargets.org/target/ENSG00000134882 | Database | Aggregates disease-target associations for UBAC2, including asthma, childhood-onset asthma, psoriasis, actinic keratosis, and hypothyroidism, useful for prioritizing translational hypotheses. (pqac-00000000) | Example association scores from excerpt: asthma 0.4426; hypothyroidism 0.3475; actinic keratosis 0.3268; psoriasis 0.3055; childhood-onset asthma 0.3054; 5 literature-linked evidences per listed disease. (pqac-00000000) | Useful overview, but database evidence is heterogeneous and should not be treated as proof of causality without examining underlying studies. |


*Table: This table summarizes the main evidence base for human UBAC2 (Q8NBM4), highlighting the 2024 ER-phagy discovery paper, the 2019 Wnt/ERAD study, key reviews, and disease-genetics sources. It is useful for quickly separating direct mechanistic evidence from review synthesis and locus-level association data.*